- Email: [email protected]
5385885 Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
PATENT ABSTRACTS
5384308 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING Henkin R STATES
Bethesda, MD, 20817, UNITED
There is described herein a wound healing enhancing medicinal composition formulated from the salivary protein Lumicarmine. Lumicarmine is a phosphogiyeoprotein with a molecular weight of 34.5 kD. About 80% of the total amino acid residues are proline glycine and glntamic acid and another 10% are lysine and arginine. Lumicarmine stains pink violet after gel electrophoresis and staining with Coomassie Brilliant Blue R-250 dye.
811
The present invention provides methods for inhibiting smooth muscle cell proliferation, particularly smooth muscle cells present in blood vessel walls. A compound capable of inhibiting blood factor Xa is administered to the smooth muscle cells in an amount effective to inhibit proliferation of the cells. The compound capable of inhibiting blood factor Xa is preferably antistasin or tick anticoagulant peptide (TAP). In other aspects the present invention provides methods for treating atherosclerotic lesions and atherosclerusis, and methods of treating narrowing of the lumen of a blood vessel wherein the narrowing is caused at least in part by hyperplasia of smooth muscle cells in the wall of the blood vessel.
5385732 VARIANTS OF TISSUE PLASMINOGEN ACTIVATOR, COMPOSITIONS AND METHODS OF USE FOR SAME 5386027 Anderson Stephen: Brady Kevin M; Keyt Bruce A; Presta Leonard G Princeton, NJ, UNITED STATES Assigned to Genemech Inc A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glyeosylation sites in regions that are not glycosylated in the native molecule. DNA sequences can be prepared that encode the variants, as well as expression vectors incorporating the D N A sequences, and host ceils transformed with the expression vectors. The variants may be used in a pharmaceutical preparation to treat a vascular disease or condition in patients.
5385885 INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION B Y A N T I S T A S I N AND TICK A N T I C O A G U L A N T PEPTIDE Gasic Gregory P; Gasic Gabriel J; Gasic Tatiana B San Diego, CA, 92130, U N I T E D S T A T E S
CARBOHYDRATE RECEPTOR FOR BACTERIA AND METHOD FOR USE THEREOF Krivan Howard; Giusburg Victo; Roberts David Rockville, MD, UNITED STATES Assigned to The United States of America as represented by the Department of Health & Human Sexvices A carbohydrate receptor for pathogenic bacteria is a purified carbohydrate compound that is a member selected from the group consisting of fucosyl-asialo GM1, asialo GM1, and asialo GM2. The receptor can be included in a composition having a pharmaceutically acceptable carrier. The receptor may be used for purifying, detecting, or removing bacteria from diseased tissue. The structure of the receptor is N-acetylngalctosaminebeta- 1-4-galactose-beta-1-4-glucose, abbreviated GalNAc betal-4Gni betal-4Glc. The receptor is present in human and animal tissues as complex molecule and can serve as the attachment site for bacterial infection. For example, fucosyl-asialo GMl,asialo GM1, and asialo GM2 are three biological molecules which occur in cell membranes and contain the carbohydrate receptor.
5384308 COMPOSITION AND METHOD FOR ENHANCING WOUND HEALING Henkin R STATES
Bethesda, MD, 20817, UNITED
There is described herein a wound healing enhancing medicinal composition formulated from the salivary protein Lumicarmine. Lumicarmine is a phosphogiyeoprotein with a molecular weight of 34.5 kD. About 80% of the total amino acid residues are proline glycine and glntamic acid and another 10% are lysine and arginine. Lumicarmine stains pink violet after gel electrophoresis and staining with Coomassie Brilliant Blue R-250 dye.
811
The present invention provides methods for inhibiting smooth muscle cell proliferation, particularly smooth muscle cells present in blood vessel walls. A compound capable of inhibiting blood factor Xa is administered to the smooth muscle cells in an amount effective to inhibit proliferation of the cells. The compound capable of inhibiting blood factor Xa is preferably antistasin or tick anticoagulant peptide (TAP). In other aspects the present invention provides methods for treating atherosclerotic lesions and atherosclerusis, and methods of treating narrowing of the lumen of a blood vessel wherein the narrowing is caused at least in part by hyperplasia of smooth muscle cells in the wall of the blood vessel.
5385732 VARIANTS OF TISSUE PLASMINOGEN ACTIVATOR, COMPOSITIONS AND METHODS OF USE FOR SAME 5386027 Anderson Stephen: Brady Kevin M; Keyt Bruce A; Presta Leonard G Princeton, NJ, UNITED STATES Assigned to Genemech Inc A fibrinolytically active amino acid sequence variant of a plasminogen activator is prepared that has one or more glyeosylation sites in regions that are not glycosylated in the native molecule. DNA sequences can be prepared that encode the variants, as well as expression vectors incorporating the D N A sequences, and host ceils transformed with the expression vectors. The variants may be used in a pharmaceutical preparation to treat a vascular disease or condition in patients.
5385885 INHIBITION OF SMOOTH MUSCLE CELL PROLIFERATION B Y A N T I S T A S I N AND TICK A N T I C O A G U L A N T PEPTIDE Gasic Gregory P; Gasic Gabriel J; Gasic Tatiana B San Diego, CA, 92130, U N I T E D S T A T E S
CARBOHYDRATE RECEPTOR FOR BACTERIA AND METHOD FOR USE THEREOF Krivan Howard; Giusburg Victo; Roberts David Rockville, MD, UNITED STATES Assigned to The United States of America as represented by the Department of Health & Human Sexvices A carbohydrate receptor for pathogenic bacteria is a purified carbohydrate compound that is a member selected from the group consisting of fucosyl-asialo GM1, asialo GM1, and asialo GM2. The receptor can be included in a composition having a pharmaceutically acceptable carrier. The receptor may be used for purifying, detecting, or removing bacteria from diseased tissue. The structure of the receptor is N-acetylngalctosaminebeta- 1-4-galactose-beta-1-4-glucose, abbreviated GalNAc betal-4Gni betal-4Glc. The receptor is present in human and animal tissues as complex molecule and can serve as the attachment site for bacterial infection. For example, fucosyl-asialo GMl,asialo GM1, and asialo GM2 are three biological molecules which occur in cell membranes and contain the carbohydrate receptor.